Roche company

Charging to the Frontline
News & Features

Charging to the Frontline

Chris Anderson -
0
Roche Partners with Alnylam to Develop RNAi Hypertension Therapy
Molecular Dx

Roche Partners with Alnylam to Develop RNAi Hypertension Therapy

Helen Albert -
0
EC Approves Roche’s Bispecific Antibody Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
News & Features

EC Approves Roche’s Bispecific Antibody Columvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Chris Anderson -
0
U.S. Encouragement for Blood-Based Cancer Biomarker
Molecular Dx

U.S. Encouragement for Blood-Based Cancer Biomarker

Anita Chakraverty -
0
Sarepta Gets Adcomm Backing for Duchenne Gene Therapy
News & Features

Sarepta Gets Adcomm Backing for Duchenne Gene Therapy

Malorye Branca -
0
Real-World Data: The Secret Sauce for Rare Disease Research?
Informatics

Real-World Data: The Secret Sauce for Rare Disease Research?

Malorye Branca -
0
Roche Bi-Specific Antibody Approved by FDA for a Relapsed or Refractory Form of Non-Hodgkin Lymphoma
News & Features

Roche Bi-Specific Antibody Approved by FDA for a Relapsed or Refractory Form of Non-Hodgkin Lymphoma

Chris Anderson -
0
Roche’s Alzheimer’s Drug Fails to Shine at Phase III
News & Features

Roche’s Alzheimer’s Drug Fails to Shine at Phase III

Helen Albert -
0
Roche Inks Potential $900 Million+ Deal with HOOPIKA for Multi-KRAS Mutation Approach
News & Features

Roche Inks Potential $900 Million+ Deal with HOOPIKA for Multi-KRAS Mutation Approach

Malorye Branca -
0
Tavros, Vividion to Collaborate on Previously Undruggable Oncology Targets
News & Features

Tavros, Vividion to Collaborate on Previously Undruggable Oncology Targets

Chris Anderson -
0
1234Page 1 of 4

Related Content

Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.
Inside Precision Medicine